LIVE HEALTHY
MEDIA
ABBOTT INDIA LTD
PRODUCTS
CAREERS
ABOUT ABBOTT
Business: Abbott India Limited
MOLECULE: Vi-Capsular Polysaccharide of S. typhi Ty2 conjugated to Tetanus Toxoid + Sodium chloride + water
FORM: Pre Filled Syringe
STRENGTH: Each 0.5 mL prefilled syringe contains purified Vi-Capsular Polysaccharide of S. typhi Ty2 conjugated to Tetanus Toxoid 25 μg, Sodium chloride 4.5 mg and water for Injections q.s. to 0.5 mL.
BUSINESS AREAS: PHARMACEUTICALS ABBOTT INDIA LIMITED,VACCINE
THERAPY AREAS: RESPIRATORY,VACCINE
MOLECULE: A/California/7/2009 (H1N1)pdm09, A/Texas/50/2012 (H3N2), B/Massachusetts/2/2012
FORM: Injection
STRENGTH: 0.5 ml prefilled syringe
BUSINESS AREAS: PHARMACEUTICALS
THERAPY AREAS: VACCINE
MOLECULE: Influenza virus surface antigens (hemagglutinin and neuraminidase) of the following strains (propagated in fertilized hens' eggs from healthy chicken flocks) A/California/7/2009 (H1N1)pdm09-like strain (A/California/ 7/2009, X-181)+ A/Hong Kong/4801/2014 (H3N2)-like strain (A/New Caledonia/71/2014, X-257A) + B/Brisbane/60/2008-like strain(B/Brisbane/60/2008, wild type)
FORM: Pre filled Syringe
STRENGTH: Influenza virus surface antigens (hemagglutinin and neuraminidase) of the following strains (propagated in fertilized hens' eggs from healthy chicken flocks) A/California/7/2009 (H1N1)pdm09-like strain (A/California/ 7/2009, X-181) 7.5 mcg HA, A/Hong Kong/4801/2014 (H3N2)-like strain (A/New Caledonia/71/2014, X-257A) 7.5 mcg HA, B/Brisbane/60/2008-like strain(B/Brisbane/60/2008, wild type) 7.5 mcg HA per 0.25 mL dose. This vaccine complies with the WHO recommendation (northern hemisphere) and competent authority decision for the 2016/2017 season.
STRENGTH: Influenza virus surface antigens (hemagglutinin and neuraminidase) of the following strains (propagated in fertilized hens' eggs from healthy chicken flocks) A/California/7/2009 (H1N1)pdm09-like strain (A/California/ 7/2009, X-181) 15 mcg HA, A/Hong Kong/4801/2014 (H3N2)-like strain (A/New Caledonia/71/2014, X-257A) 15 mcg HA, B/Brisbane/60/2008-like strain(B/Brisbane/60/2008, wild type) 15 mcg HA per 0.5 mL dose. This vaccine complies with the WHO recommendation (northern hemisphere) and competent authority decision for the 2016/2017 season.
MOLECULE: Purified, inactivated Japanese Encephalitis Virus protein (JE strain 821564-XY) + Aluminum Hydroxide gel + Thiomersal (Preservative) + Phosphate buffered saline
FORM: Vial
STRENGTH: Each Dose of 0.5 mL contains: Purified, inactivated Japanese Encephalitis Virus protein NLT 5.0 μg (JE strain 821564-XY), Aluminum Hydroxide gel as Al+++ IP 0.25 mg, Thiomersal (Preservative) IP 0.025 mg, Phosphate buffered saline q.s. to 0.5 ml.
MOLECULE: Diphtheria Toxoid + Tetanus Toxoid + B. pertussis (Whole cell inactivated) + HBsAg (rDNA) + Hib PRP-TT Conjugate + Aluminium Phosphate gel as Aluminium (Al+++) + Thiomersal
STRENGTH: Pre-filled syringe of 0.5 ml. Each syringe contains Diphtheria, Tetanus, Pertussis (Whole Cell), Hepatitis B (rDNA) and Haemophilus Influenzae type b Conjugate Vaccine (Adsorbed) I.P. Each dose of 0.5 mL contains: Diphtheria Toxoid 20 Lf to <30 Lf ( 30 IU), Tetanus Toxoid 5 Lf to 25 Lf ( 60 IU), B. pertussis (Whole cell inactivated) 4 IU, HBsAg (rDNA) 10 μg, Hib PRP-TT Conjugate 10 μg, Aluminium Phosphate gel as Aluminium (Al+++) 0.3 mg, Thiomersal IP 0.021 mg to 0.029 mg.
THERAPY AREAS: GI & HEPATO,VACCINE
MOLECULE: Rotavirus 116E NLT 105.0 FFU + Potassium phosphate monobasic + Potassium phosphate dibasic + Sucrose + Potassium L-glutamate monohydrate + Neomycin sulphate + Kanamycin sulphate + Dulbecco’s Modi ed Eagle’s Medium + water
STRENGTH: Each 0.5 ml contains Rotavirus 116E NLT 105.0 FFU, Potassium phosphate monobasic IP 0.258 mg, Potassium phosphate dibasic IP 0.625 mg, Sucrose IP 37.31 mg, Potassium L-glutamate monohydrate 1.0 mg, Neomycin sulphate IP 15 μg, Kanamycin sulphate IP 15 μg, Dulbecco’s Modi ed Eagle’s Medium 4.4 mg and water for Injection IP q.s, pH is in the range of 7.2 to 8.0.
Please be aware that the website you have requested is intended for the residents of a particular country or region, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of those products that are not approved in other countries or regions. The website you have requested also may not be optimized for your specific screen size.
Links which take you out of Abbott worldwide websites are not under the control of Abbott, and Abbott is not responsible for the contents of any such site or any further links from such site. Abbott is providing these links to you only as a convenience, and the inclusion of any link does not imply endorsement of the linked site by Abbott. The website that you have requested also may not be optimized for your screen size.
Asset Warning